相似文献
1
Discovery and validation of new molecular targets in treating dyslipidemia: the role of human genetics.
Trends Cardiovasc Med. 2009 Aug;19(6):195-201. doi: 10.1016/j.tcm.2009.12.003.
2
Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.
Vasc Health Risk Manag. 2013;9:617-70. doi: 10.2147/VHRM.S37119. Epub 2013 Oct 21.
3
Triglyceride-rich lipoproteins and HDL: what do recent trials tell us?
Atherosclerosis. 2013 Jun;228(2):329-31. doi: 10.1016/j.atherosclerosis.2013.03.011. Epub 2013 Mar 22.
4
CETP-Inhibition and HDL-Cholesterol: A Story of CV Risk or CV Benefit, or Both.
Clin Pharmacol Ther. 2018 Aug;104(2):297-300. doi: 10.1002/cpt.1118. Epub 2018 Jun 27.
5
Surprises From Genetic Analyses of Lipid Risk Factors for Atherosclerosis.
Circ Res. 2016 Feb 19;118(4):579-85. doi: 10.1161/CIRCRESAHA.115.306398.
6
From lipid locus to drug target through human genomics.
Cardiovasc Res. 2018 Jul 15;114(9):1258-1270. doi: 10.1093/cvr/cvy120.
7
Mendelian randomization to assess causal effects of blood lipids on coronary heart disease: lessons from the past and applications to the future.
Curr Opin Endocrinol Diabetes Obes. 2016 Apr;23(2):124-30. doi: 10.1097/MED.0000000000000230.
8
Discovery Approaches for Novel Dyslipidemia Drugs.
Curr Drug Discov Technol. 2015;12(2):90-116. doi: 10.2174/1570163812666150702121809.
9
Lipid-lowering therapies for aortic stenosis: a drug-target Mendelian randomization study.
Eur Heart J Cardiovasc Pharmacother. 2025 Mar 13;11(2):136-142. doi: 10.1093/ehjcvp/pvae092.
10
Rare LPL gene variants attenuate triglyceride reduction and HDL cholesterol increase in response to fenofibric acid therapy in individuals with mixed dyslipidemia.
Atherosclerosis. 2014 Jun;234(2):249-53. doi: 10.1016/j.atherosclerosis.2014.03.010. Epub 2014 Mar 22.
引用本文的文献
1
Polygenic modelling of treatment effect heterogeneity.
Genet Epidemiol. 2020 Nov;44(8):868-879. doi: 10.1002/gepi.22347. Epub 2020 Aug 10.
2
CETP, LIPC, and SCARB1 variants in individuals with extremely high high-density lipoprotein-cholesterol levels.
Sci Rep. 2019 Jul 29;9(1):10915. doi: 10.1038/s41598-019-47456-2.
3
Cholesterol efflux alterations in adolescent obesity: role of adipose-derived extracellular vesical microRNAs.
J Transl Med. 2019 Jul 22;17(1):232. doi: 10.1186/s12967-019-1980-6.
4
Identification of eight genetic variants as novel determinants of dyslipidemia in Japanese by exome-wide association studies.
Oncotarget. 2017 Jun 13;8(24):38950-38961. doi: 10.18632/oncotarget.17159.
5
Association of genetic variants influencing lipid levels with coronary artery disease in Japanese individuals.
PLoS One. 2012;7(9):e46385. doi: 10.1371/journal.pone.0046385. Epub 2012 Sep 26.
6
Association of a polymorphism of BTN2A1 with dyslipidemia in East Asian populations.
Exp Ther Med. 2011 Jul;2(4):745-749. doi: 10.3892/etm.2011.266. Epub 2011 May 12.
7
Impact of mifepristone, a glucocorticoid/progesterone antagonist, on HDL cholesterol, HDL particle concentration, and HDL function.
J Clin Endocrinol Metab. 2012 May;97(5):1598-605. doi: 10.1210/jc.2011-2813. Epub 2012 Mar 7.
8
Mining the LIPG allelic spectrum reveals the contribution of rare and common regulatory variants to HDL cholesterol.
PLoS Genet. 2011 Dec;7(12):e1002393. doi: 10.1371/journal.pgen.1002393. Epub 2011 Dec 8.
9
The genetics of common kidney disease: a pathway toward clinical relevance.
Nat Rev Nephrol. 2011 Jun 28;7(8):458-68. doi: 10.1038/nrneph.2011.85.
10
PON-dering differences in HDL function in coronary artery disease.
J Clin Invest. 2011 Jul;121(7):2545-8. doi: 10.1172/JCI57671. Epub 2011 Jun 23.
本文引用的文献
1
Extended-release niacin or ezetimibe and carotid intima-media thickness.
N Engl J Med. 2009 Nov 26;361(22):2113-22. doi: 10.1056/NEJMoa0907569. Epub 2009 Nov 15.
2
Functional lecithin: cholesterol acyltransferase is not required for efficient atheroprotection in humans.
Circulation. 2009 Aug 18;120(7):628-35. doi: 10.1161/CIRCULATIONAHA.108.818143.
3
Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.
JAMA. 2009 Jul 22;302(4):412-23. doi: 10.1001/jama.2009.1063.
4
Mendelian randomization: nature's randomized trial in the post-genome era.
JAMA. 2009 Jun 10;301(22):2386-8. doi: 10.1001/jama.2009.812.
5
Genetically elevated lipoprotein(a) and increased risk of myocardial infarction.
JAMA. 2009 Jun 10;301(22):2331-9. doi: 10.1001/jama.2009.801.
6
A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates.
Proc Natl Acad Sci U S A. 2009 Jun 16;106(24):9820-5. doi: 10.1073/pnas.0903849106. Epub 2009 May 14.
7
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
Lancet. 2009 Apr 4;373(9670):1175-82. doi: 10.1016/S0140-6736(09)60447-5. Epub 2009 Mar 28.
8
An uncertain future for cardiovascular drug development?
N Engl J Med. 2009 Mar 19;360(12):1169-71. doi: 10.1056/NEJMp0808414.
9
Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease.
Nat Genet. 2009 Mar;41(3):283-5. doi: 10.1038/ng.314. Epub 2009 Feb 8.
10
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants.
Nat Genet. 2009 Mar;41(3):334-41. doi: 10.1038/ng.327. Epub 2009 Feb 8.
Zotero 插件